碳酸锂缓释片联合丙戊酸镁缓释片治疗双相情感障碍躁狂发作的临床效果及对患者认知功能的影响

doi:10.3969/j.issn.1671-7171.2025.04.020

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1218 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨碳酸锂缓释片联合丙戊酸镁缓释片治疗双相情感障碍躁狂发作的临床效果及对患者认知功能的影响。【方法】选择2022年3月至2024年3月本院收治的100例双相情感障碍躁狂发作患者,根据随机数字表法将患者分为对照组和观察组,每组50例。对照组予以碳酸锂缓释片治疗,观察组予以碳酸锂缓释片联合丙戊酸镁缓释片治疗,比较两组临床疗效、认知功能[蒙特利尔认知评估量表(MoCA)评分]、躁狂程度[贝克-拉范森躁狂量表(BRMS)评分]、实验室指标[甲状腺素(TH)、促甲状腺激素(TSH)、促肾上腺皮质激素(ACTH)、皮质醇(Cor)]、不良反应发生率。【结果】治疗后,观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组MoCA评分高于治疗前,BRMS评分低于治疗前,且观察组MoCA评分高于对照组,BRMS评分低于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清TH、ACTH、Cor水平低于治疗前,TSH水平高于治疗前,观察组血清TH、ACTH、Cor水平低于对照组,TSH水平高于对照组,差异有统计学意义(P<0.05)。观察组、对照组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】碳酸锂缓释片联合丙戊酸镁缓释片治疗双相情感障碍躁狂发作的临床疗效较好,可改善患者认知功能和躁狂症状,调节神经内分泌功能,且安全性较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周健

关键词 ：双相情感障碍, 碳酸锂, 丙戊酸, 认知, 治疗结果

Abstract：【Objective】To explore the clinical effect of lithium carbonate sustained-release tablets combined with magnesium valproate sustained-release tablets in the treatment of manic episodes of bipolar disorder and its influence on the cognitive function of patients.【Methods】One hundred patients with manic episodes of bipolar disorder admitted to our hospital from March 2022 to March 2024 were selected and divided into the control group and the observation group according to the random number table method, with 50 cases in each group. The control group was treated with lithium carbonate sustained-release tablets, while the observation group was treated with lithium carbonate sustained-release tablets combined with magnesium valproate sustained-release tablets. The clinical efficacy, cognitive function [Montreal Cognitive Assessment Scale (MoCA) score], degree of mania [Beck and Raffenson Mania Scale (BRMS) score], laboratory indicators [thyroid hormone (TH), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), cortisol (Cor)], and incidence of adverse reactions were compared between the two groups. 【Results】After treatment, the total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the MoCA scores of both groups were higher than those before treatment, and the BRMS scores were lower than those before treatment. Moreover, the MoCA score of the observation group was higher than that of the control group, and the BRMS score was lower than that of the control group. The differences were statistically significant (P<0.05). After treatment, the levels of serum TH, ACTH and Cor in both groups were lower than those before treatment, and the level of TSH was higher than that before treatment. The levels of serum TH, ACTH and Cor in the observation group were lower than those in the control group, and the level of TSH was higher than that in the control group. The differences were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). 【Conclusion】The combination of lithium carbonate sustained-release tablets and magnesium valproate sustained-release tablets has a good clinical efficacy in the treatment of manic episodes of bipolar disorder. It can improve cognitive function and manic symptoms, regulate neuroendocrine function, and has good safety.

Key words： Bipolar Disorder Lithium Carbonate Valproic Acid Cognition Treatment Outcome

收稿日期: 2024-11-18

中图分类号:

R749.3

引用本文:

周健. 碳酸锂缓释片联合丙戊酸镁缓释片治疗双相情感障碍躁狂发作的临床效果及对患者认知功能的影响[J]. 医学临床研究, 2025, 42(4): 630-632.
ZHOU Jian. The Clinical Effect of Lithium Carbonate Sustained-Release Tablets Combined with Magnesium Valproate Sustained-release Tablets in the Treatment of Manic Episodes of Bipolar Disorder and its Influence on the Cognitive Function of Patients. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 630-632.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.04.020 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I4/630

[1] 兰寒菊,苏文生,蓝军. 丙戊酸镁治疗双相情感障碍对患者血清总胆红素、白蛋白、炎性因子水平和生活质量的影响[J].中国医药导报,2019(11):112-115.
[2] 卜杨,胡光华. 碳酸锂联合富马酸喹硫平治疗双相情感障碍躁狂发作的临床研究[J].临床研究,2023,31(1):71-74.
[3] 钟丽,王艺,张清盛. 喹硫平联合丙戊酸镁治疗双相情感障碍躁狂发作临床观察[J].中国药业,2023,32(17):90-93.
[4] 汪斌,龚雪. 丙戊酸镁与碳酸锂治疗双相情感障碍躁狂发作的疗效比较[J].临床合理用药,2024,17(9):54-57.
[5] 尹冬青,贾竑晓. 双相情感障碍中医证候辨证分型标准专家共识[J].现代中医临床,2021,28(6):1-8.
[6] 高海波,王刚,陈莎莎,等.双相情感障碍患者血清甲状腺素、泌乳素、多巴胺水平变化及与冲动攻击行为关系[J].临床误诊误治,2022,35(5):112-116.
[7] 徐金国,乐守江. 丙戊酸钠联合喹硫平对双相情感障碍伴躁狂发作患者躁狂程度及血清BDNF、IL-4、IL-10水平的影响[J].现代医学与健康研究(电子版),2021,5(5):78-80.
[8] 曹杰,罗琦. 碳酸锂联合喹硫平治疗男性双相情感障碍患者的临床效果观察[J].当代医学,2019,25(18):169-170.
[9] 陈耀毅. 碳酸锂缓释片与丙戊酸镁缓释片分别联合奥氮平片治疗双相情感障碍的疗效比较[J].临床合理用药,2023,16(25):71-74.
[10] 汪敏涛,胡代楠. 丙戊酸镁缓释片、碳酸锂缓释片分别联合奥氮平片治疗双相情感障碍的临床对比研究[J].药品评价,2022,19(17):1073-1075.
[11] 张俊丽,赵成学,王炳琛. 丙戊酸镁缓释片、碳酸锂缓释片联合心理干预治疗双相情感障碍的临床疗效[J].医学临床研究,2024,41(6):943-945.
[12] 邵国艳. 碳酸锂缓释片联合丙戊酸镁缓释片治疗双相情感障碍躁狂发作患者的疗效分析[J].现代诊断与治疗,2021,32(8):1210-1212.
[13] 贾四杰. 丙戊酸镁缓释片联合碳酸锂治疗双相情感障碍躁狂发作患者的临床效果[J].河南医学研究,2021,30(15):2820-2822.
[14] 左燕,李方捷. 碳酸锂联合丙戊酸镁治疗双相情感障碍躁狂发作的疗效及对血清BDNF、认知功能的影响[J].检验医学与临床,2024,21(1):99-102.